Rein Therapeutics Inc.
General ticker "RNTX" information:
- Sector: Health Care
- Industry: Medical - Pharmaceuticals
- Capitalization: $30.3M (TTM average)
Rein Therapeutics Inc. does not follow the US Stock Market performance with the rate: -24.7%.
Estimated limits based on current volatility of 3.8%: low 0.77$, high 0.83$
Factors to consider:
- Total employees count: 10 (-9.1%) as of 2025
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Going concern doubt, Supply chain disruptions
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.83$, 2.18$]
- 2026-12-31 to 2027-12-31 estimated range: [0.74$, 1.94$]
Short-term RNTX quotes
Long-term RNTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $16.28MM | $65.11MM | $50.63MM |
| Operating Income | $-16.28MM | $-65.11MM | $-50.63MM |
| Non-Operating Income | $0.54MM | $0.69MM | $0.05MM |
| R&D Expense | $3.99MM | $14.25MM | $11.03MM |
| Income(Loss) | $-15.73MM | $-64.43MM | $-50.58MM |
| Taxes | $0.00MM | $-1.54MM | $-0.71MM |
| Net Income(Loss)* | $-15.73MM | $-62.88MM | $-49.87MM |
| Stockholders Equity | $6.89MM | $54.39MM | $16.92MM |
| Assets | $106.01MM | $69.24MM | $24.16MM |
| Operating Cash Flow | $-19.81MM | $-22.29MM | $-19.36MM |
| Investing Cash Flow | $16.20MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $15.79MM | $17.82MM | $9.76MM |
| Earnings Per Share** | $-3.42 | $-3.51 | $-1.96 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.